nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.725	1	CiPCiCtD
Temsirolimus—ABCB1—Vismodegib—skin cancer	0.0224	0.142	CbGbCtD
Temsirolimus—CYP3A4—Temozolomide—skin cancer	0.0194	0.123	CbGbCtD
Temsirolimus—CYP3A4—Imiquimod—skin cancer	0.0194	0.123	CbGbCtD
Temsirolimus—CYP2D6—Vemurafenib—skin cancer	0.0167	0.106	CbGbCtD
Temsirolimus—CYP3A4—Vismodegib—skin cancer	0.0134	0.0852	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0125	0.079	CbGbCtD
Temsirolimus—CYP3A7—Docetaxel—skin cancer	0.0125	0.079	CbGbCtD
Temsirolimus—ABCB1—Dactinomycin—skin cancer	0.0118	0.0747	CbGbCtD
Temsirolimus—CYP3A4—Vemurafenib—skin cancer	0.0106	0.0673	CbGbCtD
Temsirolimus—CYP3A5—Docetaxel—skin cancer	0.00936	0.0593	CbGbCtD
Temsirolimus—ABCB1—Docetaxel—skin cancer	0.00609	0.0386	CbGbCtD
Temsirolimus—CYP3A4—Docetaxel—skin cancer	0.00365	0.0231	CbGbCtD
Temsirolimus—MTOR—leg—skin cancer	0.00313	0.127	CbGeAlD
Temsirolimus—MTOR—forelimb—skin cancer	0.0031	0.126	CbGeAlD
Temsirolimus—MTOR—hindlimb—skin cancer	0.00279	0.113	CbGeAlD
Temsirolimus—MTOR—appendage—skin cancer	0.0024	0.0972	CbGeAlD
Temsirolimus—MTOR—blood vessel—skin cancer	0.00133	0.0541	CbGeAlD
Temsirolimus—MTOR—neck—skin cancer	0.000954	0.0387	CbGeAlD
Temsirolimus—FKBP1A—nipple—skin cancer	0.000867	0.0352	CbGeAlD
Temsirolimus—FKBP1A—neck—skin cancer	0.000858	0.0348	CbGeAlD
Temsirolimus—MTOR—connective tissue—skin cancer	0.000684	0.0277	CbGeAlD
Temsirolimus—MTOR—epithelium—skin cancer	0.000649	0.0263	CbGeAlD
Temsirolimus—MTOR—skin of body—skin cancer	0.000618	0.025	CbGeAlD
Temsirolimus—FKBP1A—connective tissue—skin cancer	0.000615	0.025	CbGeAlD
Temsirolimus—FKBP1A—epithelium—skin cancer	0.000584	0.0237	CbGeAlD
Temsirolimus—MTOR—mammalian vulva—skin cancer	0.000563	0.0228	CbGeAlD
Temsirolimus—FKBP1A—skin of body—skin cancer	0.000555	0.0225	CbGeAlD
Temsirolimus—FKBP1A—mammalian vulva—skin cancer	0.000507	0.0205	CbGeAlD
Temsirolimus—MTOR—lymphoid tissue—skin cancer	0.0005	0.0203	CbGeAlD
Temsirolimus—MTOR—female reproductive system—skin cancer	0.000482	0.0196	CbGeAlD
Temsirolimus—FKBP1A—lymphoid tissue—skin cancer	0.00045	0.0182	CbGeAlD
Temsirolimus—FKBP1A—female reproductive system—skin cancer	0.000434	0.0176	CbGeAlD
Temsirolimus—MTOR—head—skin cancer	0.000403	0.0163	CbGeAlD
Temsirolimus—FKBP1A—head—skin cancer	0.000362	0.0147	CbGeAlD
Temsirolimus—MTOR—lymph node—skin cancer	0.000282	0.0114	CbGeAlD
Temsirolimus—ABCB1—blood vessel—skin cancer	0.000278	0.0113	CbGeAlD
Temsirolimus—FKBP1A—lymph node—skin cancer	0.000254	0.0103	CbGeAlD
Temsirolimus—CYP3A4—female reproductive system—skin cancer	0.000142	0.00575	CbGeAlD
Temsirolimus—CYP2D6—female reproductive system—skin cancer	0.00014	0.00566	CbGeAlD
Temsirolimus—ABCB1—epithelium—skin cancer	0.000135	0.00548	CbGeAlD
Temsirolimus—ABCB1—mammalian vulva—skin cancer	0.000117	0.00475	CbGeAlD
Temsirolimus—CYP2D6—head—skin cancer	0.000117	0.00473	CbGeAlD
Temsirolimus—Stomatitis—Temozolomide—skin cancer	0.000112	0.00129	CcSEcCtD
Temsirolimus—Urinary tract infection—Temozolomide—skin cancer	0.000111	0.00128	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000111	0.00128	CcSEcCtD
Temsirolimus—Insomnia—Imiquimod—skin cancer	0.00011	0.00127	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00011	0.00127	CcSEcCtD
Temsirolimus—Chills—Bleomycin—skin cancer	0.000109	0.00126	CcSEcCtD
Temsirolimus—Dyspnoea—Imiquimod—skin cancer	0.000109	0.00125	CcSEcCtD
Temsirolimus—Somnolence—Imiquimod—skin cancer	0.000108	0.00125	CcSEcCtD
Temsirolimus—Erythema multiforme—Dactinomycin—skin cancer	0.000107	0.00124	CcSEcCtD
Temsirolimus—Sinusitis—Temozolomide—skin cancer	0.000107	0.00124	CcSEcCtD
Temsirolimus—Pneumonia—Fluorouracil—skin cancer	0.000106	0.00122	CcSEcCtD
Temsirolimus—Erythema—Bleomycin—skin cancer	0.000106	0.00122	CcSEcCtD
Temsirolimus—Decreased appetite—Imiquimod—skin cancer	0.000106	0.00122	CcSEcCtD
Temsirolimus—Infestation—Fluorouracil—skin cancer	0.000105	0.00122	CcSEcCtD
Temsirolimus—Infestation NOS—Fluorouracil—skin cancer	0.000105	0.00122	CcSEcCtD
Temsirolimus—Hypersensitivity—Vemurafenib—skin cancer	0.000105	0.00122	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Imiquimod—skin cancer	0.000105	0.00121	CcSEcCtD
Temsirolimus—Fatigue—Imiquimod—skin cancer	0.000105	0.00121	CcSEcCtD
Temsirolimus—Pain—Imiquimod—skin cancer	0.000104	0.0012	CcSEcCtD
Temsirolimus—ABCB1—lymphoid tissue—skin cancer	0.000104	0.00422	CbGeAlD
Temsirolimus—Dermatitis bullous—Docetaxel—skin cancer	0.000103	0.00119	CcSEcCtD
Temsirolimus—Stomatitis—Fluorouracil—skin cancer	0.000103	0.00119	CcSEcCtD
Temsirolimus—Urinary tract infection—Fluorouracil—skin cancer	0.000102	0.00118	CcSEcCtD
Temsirolimus—Conjunctivitis—Fluorouracil—skin cancer	0.000102	0.00118	CcSEcCtD
Temsirolimus—Asthenia—Vemurafenib—skin cancer	0.000102	0.00118	CcSEcCtD
Temsirolimus—Pharyngitis—Temozolomide—skin cancer	0.000102	0.00118	CcSEcCtD
Temsirolimus—Chills—Dactinomycin—skin cancer	0.000102	0.00118	CcSEcCtD
Temsirolimus—Urinary tract disorder—Temozolomide—skin cancer	0.000101	0.00117	CcSEcCtD
Temsirolimus—Oedema peripheral—Temozolomide—skin cancer	0.000101	0.00117	CcSEcCtD
Temsirolimus—Pruritus—Vemurafenib—skin cancer	0.000101	0.00117	CcSEcCtD
Temsirolimus—Connective tissue disorder—Temozolomide—skin cancer	0.000101	0.00117	CcSEcCtD
Temsirolimus—Urethral disorder—Temozolomide—skin cancer	0.000101	0.00116	CcSEcCtD
Temsirolimus—ABCB1—female reproductive system—skin cancer	0.0001	0.00407	CbGeAlD
Temsirolimus—Gastrointestinal pain—Imiquimod—skin cancer	9.96e-05	0.00115	CcSEcCtD
Temsirolimus—Epistaxis—Fluorouracil—skin cancer	9.94e-05	0.00115	CcSEcCtD
Temsirolimus—Sinusitis—Fluorouracil—skin cancer	9.89e-05	0.00114	CcSEcCtD
Temsirolimus—Erythema—Dactinomycin—skin cancer	9.89e-05	0.00114	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Docetaxel—skin cancer	9.87e-05	0.00114	CcSEcCtD
Temsirolimus—Anaemia—Bleomycin—skin cancer	9.8e-05	0.00113	CcSEcCtD
Temsirolimus—Diarrhoea—Vemurafenib—skin cancer	9.77e-05	0.00113	CcSEcCtD
Temsirolimus—Erythema multiforme—Temozolomide—skin cancer	9.71e-05	0.00112	CcSEcCtD
Temsirolimus—Abdominal pain—Imiquimod—skin cancer	9.63e-05	0.00111	CcSEcCtD
Temsirolimus—Body temperature increased—Imiquimod—skin cancer	9.63e-05	0.00111	CcSEcCtD
Temsirolimus—Eye disorder—Temozolomide—skin cancer	9.6e-05	0.00111	CcSEcCtD
Temsirolimus—Cardiac disorder—Temozolomide—skin cancer	9.53e-05	0.0011	CcSEcCtD
Temsirolimus—Leukopenia—Bleomycin—skin cancer	9.49e-05	0.0011	CcSEcCtD
Temsirolimus—Rhinitis—Fluorouracil—skin cancer	9.49e-05	0.0011	CcSEcCtD
Temsirolimus—Dizziness—Vemurafenib—skin cancer	9.44e-05	0.00109	CcSEcCtD
Temsirolimus—Pharyngitis—Fluorouracil—skin cancer	9.39e-05	0.00108	CcSEcCtD
Temsirolimus—Angiopathy—Temozolomide—skin cancer	9.32e-05	0.00108	CcSEcCtD
Temsirolimus—Immune system disorder—Temozolomide—skin cancer	9.28e-05	0.00107	CcSEcCtD
Temsirolimus—Mediastinal disorder—Temozolomide—skin cancer	9.26e-05	0.00107	CcSEcCtD
Temsirolimus—Cough—Bleomycin—skin cancer	9.25e-05	0.00107	CcSEcCtD
Temsirolimus—Chills—Temozolomide—skin cancer	9.22e-05	0.00106	CcSEcCtD
Temsirolimus—Dehydration—Docetaxel—skin cancer	9.18e-05	0.00106	CcSEcCtD
Temsirolimus—Anaemia—Dactinomycin—skin cancer	9.14e-05	0.00106	CcSEcCtD
Temsirolimus—Vomiting—Vemurafenib—skin cancer	9.08e-05	0.00105	CcSEcCtD
Temsirolimus—Dry skin—Docetaxel—skin cancer	9.05e-05	0.00105	CcSEcCtD
Temsirolimus—Chest pain—Bleomycin—skin cancer	9.02e-05	0.00104	CcSEcCtD
Temsirolimus—Myalgia—Bleomycin—skin cancer	9.02e-05	0.00104	CcSEcCtD
Temsirolimus—Rash—Vemurafenib—skin cancer	9e-05	0.00104	CcSEcCtD
Temsirolimus—Mental disorder—Temozolomide—skin cancer	9e-05	0.00104	CcSEcCtD
Temsirolimus—Dermatitis—Vemurafenib—skin cancer	8.99e-05	0.00104	CcSEcCtD
Temsirolimus—Hypersensitivity—Imiquimod—skin cancer	8.97e-05	0.00104	CcSEcCtD
Temsirolimus—Headache—Vemurafenib—skin cancer	8.95e-05	0.00103	CcSEcCtD
Temsirolimus—Malnutrition—Temozolomide—skin cancer	8.94e-05	0.00103	CcSEcCtD
Temsirolimus—Erythema—Temozolomide—skin cancer	8.94e-05	0.00103	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Docetaxel—skin cancer	8.89e-05	0.00103	CcSEcCtD
Temsirolimus—Leukopenia—Dactinomycin—skin cancer	8.85e-05	0.00102	CcSEcCtD
Temsirolimus—Dysgeusia—Temozolomide—skin cancer	8.76e-05	0.00101	CcSEcCtD
Temsirolimus—Asthenia—Imiquimod—skin cancer	8.74e-05	0.00101	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Docetaxel—skin cancer	8.71e-05	0.00101	CcSEcCtD
Temsirolimus—Oedema—Bleomycin—skin cancer	8.65e-05	0.000999	CcSEcCtD
Temsirolimus—Anaphylactic shock—Bleomycin—skin cancer	8.65e-05	0.000999	CcSEcCtD
Temsirolimus—Back pain—Temozolomide—skin cancer	8.65e-05	0.000999	CcSEcCtD
Temsirolimus—Pruritus—Imiquimod—skin cancer	8.62e-05	0.000995	CcSEcCtD
Temsirolimus—Infection—Bleomycin—skin cancer	8.59e-05	0.000993	CcSEcCtD
Temsirolimus—Dysphagia—Docetaxel—skin cancer	8.53e-05	0.000986	CcSEcCtD
Temsirolimus—Nausea—Vemurafenib—skin cancer	8.48e-05	0.00098	CcSEcCtD
Temsirolimus—Thrombocytopenia—Bleomycin—skin cancer	8.47e-05	0.000978	CcSEcCtD
Temsirolimus—Myalgia—Dactinomycin—skin cancer	8.42e-05	0.000972	CcSEcCtD
Temsirolimus—ABCB1—head—skin cancer	8.38e-05	0.0034	CbGeAlD
Temsirolimus—Diarrhoea—Imiquimod—skin cancer	8.33e-05	0.000962	CcSEcCtD
Temsirolimus—Anaemia—Temozolomide—skin cancer	8.26e-05	0.000955	CcSEcCtD
Temsirolimus—Anorexia—Bleomycin—skin cancer	8.25e-05	0.000952	CcSEcCtD
Temsirolimus—Erythema—Fluorouracil—skin cancer	8.24e-05	0.000952	CcSEcCtD
Temsirolimus—Angioedema—Temozolomide—skin cancer	8.17e-05	0.000944	CcSEcCtD
Temsirolimus—Oedema—Dactinomycin—skin cancer	8.07e-05	0.000932	CcSEcCtD
Temsirolimus—Dizziness—Imiquimod—skin cancer	8.05e-05	0.00093	CcSEcCtD
Temsirolimus—Infection—Dactinomycin—skin cancer	8.02e-05	0.000926	CcSEcCtD
Temsirolimus—Leukopenia—Temozolomide—skin cancer	8e-05	0.000924	CcSEcCtD
Temsirolimus—Neutropenia—Docetaxel—skin cancer	7.98e-05	0.000922	CcSEcCtD
Temsirolimus—Thrombocytopenia—Dactinomycin—skin cancer	7.9e-05	0.000912	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Bleomycin—skin cancer	7.88e-05	0.00091	CcSEcCtD
Temsirolimus—Cough—Temozolomide—skin cancer	7.8e-05	0.000901	CcSEcCtD
Temsirolimus—Convulsion—Temozolomide—skin cancer	7.75e-05	0.000895	CcSEcCtD
Temsirolimus—Vomiting—Imiquimod—skin cancer	7.74e-05	0.000894	CcSEcCtD
Temsirolimus—Weight decreased—Docetaxel—skin cancer	7.72e-05	0.000892	CcSEcCtD
Temsirolimus—Hypertension—Temozolomide—skin cancer	7.72e-05	0.000892	CcSEcCtD
Temsirolimus—Dyspnoea—Bleomycin—skin cancer	7.71e-05	0.000891	CcSEcCtD
Temsirolimus—Anorexia—Dactinomycin—skin cancer	7.69e-05	0.000888	CcSEcCtD
Temsirolimus—Rash—Imiquimod—skin cancer	7.68e-05	0.000887	CcSEcCtD
Temsirolimus—Dermatitis—Imiquimod—skin cancer	7.67e-05	0.000886	CcSEcCtD
Temsirolimus—Pneumonia—Docetaxel—skin cancer	7.65e-05	0.000884	CcSEcCtD
Temsirolimus—Headache—Imiquimod—skin cancer	7.63e-05	0.000881	CcSEcCtD
Temsirolimus—Anaemia—Fluorouracil—skin cancer	7.61e-05	0.000879	CcSEcCtD
Temsirolimus—Arthralgia—Temozolomide—skin cancer	7.61e-05	0.000879	CcSEcCtD
Temsirolimus—Myalgia—Temozolomide—skin cancer	7.61e-05	0.000879	CcSEcCtD
Temsirolimus—Infestation—Docetaxel—skin cancer	7.61e-05	0.000879	CcSEcCtD
Temsirolimus—Infestation NOS—Docetaxel—skin cancer	7.61e-05	0.000879	CcSEcCtD
Temsirolimus—Anxiety—Temozolomide—skin cancer	7.59e-05	0.000876	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	7.56e-05	0.000873	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Docetaxel—skin cancer	7.54e-05	0.000871	CcSEcCtD
Temsirolimus—Decreased appetite—Bleomycin—skin cancer	7.52e-05	0.000869	CcSEcCtD
Temsirolimus—Renal failure—Docetaxel—skin cancer	7.48e-05	0.000864	CcSEcCtD
Temsirolimus—Stomatitis—Docetaxel—skin cancer	7.42e-05	0.000857	CcSEcCtD
Temsirolimus—Pain—Bleomycin—skin cancer	7.4e-05	0.000854	CcSEcCtD
Temsirolimus—Conjunctivitis—Docetaxel—skin cancer	7.4e-05	0.000854	CcSEcCtD
Temsirolimus—Leukopenia—Fluorouracil—skin cancer	7.37e-05	0.000852	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Dactinomycin—skin cancer	7.35e-05	0.000849	CcSEcCtD
Temsirolimus—Oedema—Temozolomide—skin cancer	7.3e-05	0.000843	CcSEcCtD
Temsirolimus—Anaphylactic shock—Temozolomide—skin cancer	7.3e-05	0.000843	CcSEcCtD
Temsirolimus—Infection—Temozolomide—skin cancer	7.25e-05	0.000837	CcSEcCtD
Temsirolimus—Nausea—Imiquimod—skin cancer	7.23e-05	0.000835	CcSEcCtD
Temsirolimus—Epistaxis—Docetaxel—skin cancer	7.18e-05	0.000829	CcSEcCtD
Temsirolimus—Nervous system disorder—Temozolomide—skin cancer	7.16e-05	0.000827	CcSEcCtD
Temsirolimus—Thrombocytopenia—Temozolomide—skin cancer	7.14e-05	0.000825	CcSEcCtD
Temsirolimus—Convulsion—Fluorouracil—skin cancer	7.14e-05	0.000824	CcSEcCtD
Temsirolimus—Skin disorder—Temozolomide—skin cancer	7.09e-05	0.000819	CcSEcCtD
Temsirolimus—Chest pain—Fluorouracil—skin cancer	7.01e-05	0.00081	CcSEcCtD
Temsirolimus—Myalgia—Fluorouracil—skin cancer	7.01e-05	0.00081	CcSEcCtD
Temsirolimus—Decreased appetite—Dactinomycin—skin cancer	7.01e-05	0.00081	CcSEcCtD
Temsirolimus—Fatigue—Dactinomycin—skin cancer	6.96e-05	0.000803	CcSEcCtD
Temsirolimus—Anorexia—Temozolomide—skin cancer	6.96e-05	0.000803	CcSEcCtD
Temsirolimus—Pain—Dactinomycin—skin cancer	6.9e-05	0.000797	CcSEcCtD
Temsirolimus—Rhinitis—Docetaxel—skin cancer	6.85e-05	0.000791	CcSEcCtD
Temsirolimus—Body temperature increased—Bleomycin—skin cancer	6.84e-05	0.00079	CcSEcCtD
Temsirolimus—Pharyngitis—Docetaxel—skin cancer	6.78e-05	0.000783	CcSEcCtD
Temsirolimus—Urinary tract disorder—Docetaxel—skin cancer	6.75e-05	0.000779	CcSEcCtD
Temsirolimus—Oedema peripheral—Docetaxel—skin cancer	6.73e-05	0.000777	CcSEcCtD
Temsirolimus—Oedema—Fluorouracil—skin cancer	6.72e-05	0.000777	CcSEcCtD
Temsirolimus—Anaphylactic shock—Fluorouracil—skin cancer	6.72e-05	0.000777	CcSEcCtD
Temsirolimus—Connective tissue disorder—Docetaxel—skin cancer	6.71e-05	0.000775	CcSEcCtD
Temsirolimus—Urethral disorder—Docetaxel—skin cancer	6.7e-05	0.000773	CcSEcCtD
Temsirolimus—Infection—Fluorouracil—skin cancer	6.68e-05	0.000772	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Temozolomide—skin cancer	6.65e-05	0.000768	CcSEcCtD
Temsirolimus—Insomnia—Temozolomide—skin cancer	6.6e-05	0.000762	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Dactinomycin—skin cancer	6.6e-05	0.000762	CcSEcCtD
Temsirolimus—Nervous system disorder—Fluorouracil—skin cancer	6.59e-05	0.000762	CcSEcCtD
Temsirolimus—Thrombocytopenia—Fluorouracil—skin cancer	6.58e-05	0.00076	CcSEcCtD
Temsirolimus—Dyspnoea—Temozolomide—skin cancer	6.51e-05	0.000751	CcSEcCtD
Temsirolimus—Somnolence—Temozolomide—skin cancer	6.49e-05	0.000749	CcSEcCtD
Temsirolimus—Erythema multiforme—Docetaxel—skin cancer	6.46e-05	0.000746	CcSEcCtD
Temsirolimus—Anorexia—Fluorouracil—skin cancer	6.41e-05	0.00074	CcSEcCtD
Temsirolimus—Eye disorder—Docetaxel—skin cancer	6.38e-05	0.000737	CcSEcCtD
Temsirolimus—Abdominal pain—Dactinomycin—skin cancer	6.38e-05	0.000737	CcSEcCtD
Temsirolimus—Body temperature increased—Dactinomycin—skin cancer	6.38e-05	0.000737	CcSEcCtD
Temsirolimus—Hypersensitivity—Bleomycin—skin cancer	6.37e-05	0.000736	CcSEcCtD
Temsirolimus—Decreased appetite—Temozolomide—skin cancer	6.34e-05	0.000733	CcSEcCtD
Temsirolimus—Cardiac disorder—Docetaxel—skin cancer	6.34e-05	0.000732	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Temozolomide—skin cancer	6.3e-05	0.000728	CcSEcCtD
Temsirolimus—Fatigue—Temozolomide—skin cancer	6.29e-05	0.000727	CcSEcCtD
Temsirolimus—Constipation—Temozolomide—skin cancer	6.24e-05	0.000721	CcSEcCtD
Temsirolimus—Pain—Temozolomide—skin cancer	6.24e-05	0.000721	CcSEcCtD
Temsirolimus—Asthenia—Bleomycin—skin cancer	6.21e-05	0.000717	CcSEcCtD
Temsirolimus—Angiopathy—Docetaxel—skin cancer	6.2e-05	0.000716	CcSEcCtD
Temsirolimus—Immune system disorder—Docetaxel—skin cancer	6.17e-05	0.000713	CcSEcCtD
Temsirolimus—Mediastinal disorder—Docetaxel—skin cancer	6.16e-05	0.000711	CcSEcCtD
Temsirolimus—Chills—Docetaxel—skin cancer	6.13e-05	0.000708	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Fluorouracil—skin cancer	6.13e-05	0.000708	CcSEcCtD
Temsirolimus—Pruritus—Bleomycin—skin cancer	6.12e-05	0.000707	CcSEcCtD
Temsirolimus—Insomnia—Fluorouracil—skin cancer	6.08e-05	0.000702	CcSEcCtD
Temsirolimus—Dyspnoea—Fluorouracil—skin cancer	5.99e-05	0.000692	CcSEcCtD
Temsirolimus—Mental disorder—Docetaxel—skin cancer	5.98e-05	0.000691	CcSEcCtD
Temsirolimus—Somnolence—Fluorouracil—skin cancer	5.98e-05	0.00069	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Temozolomide—skin cancer	5.97e-05	0.000689	CcSEcCtD
Temsirolimus—Malnutrition—Docetaxel—skin cancer	5.95e-05	0.000687	CcSEcCtD
Temsirolimus—Erythema—Docetaxel—skin cancer	5.95e-05	0.000687	CcSEcCtD
Temsirolimus—Hypersensitivity—Dactinomycin—skin cancer	5.94e-05	0.000687	CcSEcCtD
Temsirolimus—ABCB1—lymph node—skin cancer	5.87e-05	0.00238	CbGeAlD
Temsirolimus—Decreased appetite—Fluorouracil—skin cancer	5.84e-05	0.000675	CcSEcCtD
Temsirolimus—Dysgeusia—Docetaxel—skin cancer	5.82e-05	0.000673	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Fluorouracil—skin cancer	5.8e-05	0.00067	CcSEcCtD
Temsirolimus—Asthenia—Dactinomycin—skin cancer	5.79e-05	0.000669	CcSEcCtD
Temsirolimus—Abdominal pain—Temozolomide—skin cancer	5.77e-05	0.000666	CcSEcCtD
Temsirolimus—Body temperature increased—Temozolomide—skin cancer	5.77e-05	0.000666	CcSEcCtD
Temsirolimus—Back pain—Docetaxel—skin cancer	5.75e-05	0.000664	CcSEcCtD
Temsirolimus—Pain—Fluorouracil—skin cancer	5.75e-05	0.000664	CcSEcCtD
Temsirolimus—Diarrhoea—Dactinomycin—skin cancer	5.52e-05	0.000638	CcSEcCtD
Temsirolimus—Vomiting—Bleomycin—skin cancer	5.5e-05	0.000635	CcSEcCtD
Temsirolimus—Anaemia—Docetaxel—skin cancer	5.5e-05	0.000635	CcSEcCtD
Temsirolimus—Rash—Bleomycin—skin cancer	5.45e-05	0.00063	CcSEcCtD
Temsirolimus—Dermatitis—Bleomycin—skin cancer	5.45e-05	0.000629	CcSEcCtD
Temsirolimus—Hypersensitivity—Temozolomide—skin cancer	5.38e-05	0.000621	CcSEcCtD
Temsirolimus—Leukopenia—Docetaxel—skin cancer	5.32e-05	0.000615	CcSEcCtD
Temsirolimus—Body temperature increased—Fluorouracil—skin cancer	5.32e-05	0.000614	CcSEcCtD
Temsirolimus—Asthenia—Temozolomide—skin cancer	5.24e-05	0.000605	CcSEcCtD
Temsirolimus—Cough—Docetaxel—skin cancer	5.19e-05	0.000599	CcSEcCtD
Temsirolimus—Pruritus—Temozolomide—skin cancer	5.16e-05	0.000596	CcSEcCtD
Temsirolimus—Convulsion—Docetaxel—skin cancer	5.15e-05	0.000595	CcSEcCtD
Temsirolimus—Nausea—Bleomycin—skin cancer	5.14e-05	0.000593	CcSEcCtD
Temsirolimus—Hypertension—Docetaxel—skin cancer	5.13e-05	0.000593	CcSEcCtD
Temsirolimus—Vomiting—Dactinomycin—skin cancer	5.13e-05	0.000592	CcSEcCtD
Temsirolimus—Rash—Dactinomycin—skin cancer	5.09e-05	0.000588	CcSEcCtD
Temsirolimus—Chest pain—Docetaxel—skin cancer	5.06e-05	0.000585	CcSEcCtD
Temsirolimus—Arthralgia—Docetaxel—skin cancer	5.06e-05	0.000585	CcSEcCtD
Temsirolimus—Myalgia—Docetaxel—skin cancer	5.06e-05	0.000585	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	5.03e-05	0.000581	CcSEcCtD
Temsirolimus—Diarrhoea—Temozolomide—skin cancer	4.99e-05	0.000577	CcSEcCtD
Temsirolimus—Hypersensitivity—Fluorouracil—skin cancer	4.95e-05	0.000572	CcSEcCtD
Temsirolimus—Anaphylactic shock—Docetaxel—skin cancer	4.85e-05	0.000561	CcSEcCtD
Temsirolimus—Oedema—Docetaxel—skin cancer	4.85e-05	0.000561	CcSEcCtD
Temsirolimus—Dizziness—Temozolomide—skin cancer	4.83e-05	0.000557	CcSEcCtD
Temsirolimus—Infection—Docetaxel—skin cancer	4.82e-05	0.000557	CcSEcCtD
Temsirolimus—Nausea—Dactinomycin—skin cancer	4.79e-05	0.000554	CcSEcCtD
Temsirolimus—Nervous system disorder—Docetaxel—skin cancer	4.76e-05	0.00055	CcSEcCtD
Temsirolimus—Pruritus—Fluorouracil—skin cancer	4.76e-05	0.000549	CcSEcCtD
Temsirolimus—Thrombocytopenia—Docetaxel—skin cancer	4.75e-05	0.000549	CcSEcCtD
Temsirolimus—Skin disorder—Docetaxel—skin cancer	4.71e-05	0.000544	CcSEcCtD
Temsirolimus—Vomiting—Temozolomide—skin cancer	4.64e-05	0.000536	CcSEcCtD
Temsirolimus—Anorexia—Docetaxel—skin cancer	4.63e-05	0.000534	CcSEcCtD
Temsirolimus—Rash—Temozolomide—skin cancer	4.6e-05	0.000531	CcSEcCtD
Temsirolimus—Diarrhoea—Fluorouracil—skin cancer	4.6e-05	0.000531	CcSEcCtD
Temsirolimus—Dermatitis—Temozolomide—skin cancer	4.6e-05	0.000531	CcSEcCtD
Temsirolimus—Headache—Temozolomide—skin cancer	4.57e-05	0.000528	CcSEcCtD
Temsirolimus—Dizziness—Fluorouracil—skin cancer	4.45e-05	0.000514	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Docetaxel—skin cancer	4.42e-05	0.000511	CcSEcCtD
Temsirolimus—Insomnia—Docetaxel—skin cancer	4.39e-05	0.000507	CcSEcCtD
Temsirolimus—Nausea—Temozolomide—skin cancer	4.33e-05	0.000501	CcSEcCtD
Temsirolimus—Dyspnoea—Docetaxel—skin cancer	4.33e-05	0.0005	CcSEcCtD
Temsirolimus—Somnolence—Docetaxel—skin cancer	4.31e-05	0.000498	CcSEcCtD
Temsirolimus—Vomiting—Fluorouracil—skin cancer	4.27e-05	0.000494	CcSEcCtD
Temsirolimus—Rash—Fluorouracil—skin cancer	4.24e-05	0.00049	CcSEcCtD
Temsirolimus—Dermatitis—Fluorouracil—skin cancer	4.24e-05	0.000489	CcSEcCtD
Temsirolimus—Decreased appetite—Docetaxel—skin cancer	4.22e-05	0.000487	CcSEcCtD
Temsirolimus—Headache—Fluorouracil—skin cancer	4.21e-05	0.000486	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Docetaxel—skin cancer	4.19e-05	0.000484	CcSEcCtD
Temsirolimus—Fatigue—Docetaxel—skin cancer	4.18e-05	0.000483	CcSEcCtD
Temsirolimus—Pain—Docetaxel—skin cancer	4.15e-05	0.000479	CcSEcCtD
Temsirolimus—Constipation—Docetaxel—skin cancer	4.15e-05	0.000479	CcSEcCtD
Temsirolimus—Nausea—Fluorouracil—skin cancer	3.99e-05	0.000461	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Docetaxel—skin cancer	3.97e-05	0.000458	CcSEcCtD
Temsirolimus—Body temperature increased—Docetaxel—skin cancer	3.84e-05	0.000443	CcSEcCtD
Temsirolimus—Abdominal pain—Docetaxel—skin cancer	3.84e-05	0.000443	CcSEcCtD
Temsirolimus—Hypersensitivity—Docetaxel—skin cancer	3.58e-05	0.000413	CcSEcCtD
Temsirolimus—Asthenia—Docetaxel—skin cancer	3.48e-05	0.000402	CcSEcCtD
Temsirolimus—Pruritus—Docetaxel—skin cancer	3.43e-05	0.000397	CcSEcCtD
Temsirolimus—Diarrhoea—Docetaxel—skin cancer	3.32e-05	0.000384	CcSEcCtD
Temsirolimus—Dizziness—Docetaxel—skin cancer	3.21e-05	0.000371	CcSEcCtD
Temsirolimus—Vomiting—Docetaxel—skin cancer	3.09e-05	0.000356	CcSEcCtD
Temsirolimus—Rash—Docetaxel—skin cancer	3.06e-05	0.000353	CcSEcCtD
Temsirolimus—Dermatitis—Docetaxel—skin cancer	3.06e-05	0.000353	CcSEcCtD
Temsirolimus—Headache—Docetaxel—skin cancer	3.04e-05	0.000351	CcSEcCtD
Temsirolimus—Nausea—Docetaxel—skin cancer	2.88e-05	0.000333	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.32e-05	0.00436	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RHOU—skin cancer	2.32e-05	0.00435	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—skin cancer	2.26e-05	0.00423	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—FOXO4—skin cancer	2.22e-05	0.00415	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—CDK4—skin cancer	2.21e-05	0.00414	CbGpPWpGaD
Temsirolimus—MTOR—TSLP Signaling Pathway—IL6—skin cancer	2.19e-05	0.0041	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CSPG4—skin cancer	2.18e-05	0.00409	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—TP53—skin cancer	2.14e-05	0.00401	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—skin cancer	2.07e-05	0.00389	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	2.06e-05	0.00386	CbGpPWpGaD
Temsirolimus—MTOR—mTOR signaling pathway—KRAS—skin cancer	2.05e-05	0.00384	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—HRAS—skin cancer	2.04e-05	0.00383	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—TP53—skin cancer	2.03e-05	0.00381	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTCH2—skin cancer	2.01e-05	0.00378	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—BRAF—skin cancer	1.95e-05	0.00366	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—NRAS—skin cancer	1.94e-05	0.00364	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—NRAS—skin cancer	1.89e-05	0.00354	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—skin cancer	1.87e-05	0.00351	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—IL6—skin cancer	1.86e-05	0.00349	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—BRAF—skin cancer	1.85e-05	0.00346	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—BRAF—skin cancer	1.85e-05	0.00346	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—skin cancer	1.84e-05	0.00346	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—NRAS—skin cancer	1.82e-05	0.00342	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—NRAS—skin cancer	1.82e-05	0.00342	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—skin cancer	1.76e-05	0.0033	CbGpPWpGaD
Temsirolimus—MTOR—AMPK Signaling—TP53—skin cancer	1.76e-05	0.00329	CbGpPWpGaD
Temsirolimus—MTOR—TSH signaling pathway—HRAS—skin cancer	1.74e-05	0.00326	CbGpPWpGaD
Temsirolimus—MTOR—mTOR signaling pathway—HRAS—skin cancer	1.74e-05	0.00326	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—BRAF—skin cancer	1.72e-05	0.00322	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—KRAS—skin cancer	1.67e-05	0.00314	CbGpPWpGaD
Temsirolimus—MTOR—CDC42 signaling events—HRAS—skin cancer	1.66e-05	0.00311	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—NRAS—skin cancer	1.64e-05	0.00308	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—KRAS—skin cancer	1.63e-05	0.00305	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	1.62e-05	0.00303	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	1.62e-05	0.00303	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—skin cancer	1.61e-05	0.00302	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—HRAS—skin cancer	1.57e-05	0.00295	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—KRAS—skin cancer	1.57e-05	0.00294	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—KRAS—skin cancer	1.57e-05	0.00294	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.56e-05	0.00292	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	1.53e-05	0.00287	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—GLI2—skin cancer	1.53e-05	0.00286	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—NRAS—skin cancer	1.53e-05	0.00286	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	1.52e-05	0.00286	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—NRAS—skin cancer	1.52e-05	0.00284	CbGpPWpGaD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—skin cancer	1.49e-05	0.0028	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—SHH—skin cancer	1.48e-05	0.00278	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ENO2—skin cancer	1.48e-05	0.00278	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MC1R—skin cancer	1.46e-05	0.00273	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—GLI1—skin cancer	1.44e-05	0.00269	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—TLR7—skin cancer	1.43e-05	0.00268	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—HRAS—skin cancer	1.42e-05	0.00267	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—KRAS—skin cancer	1.41e-05	0.00265	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—CDK4—skin cancer	1.41e-05	0.00265	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	1.39e-05	0.00261	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.38e-05	0.00259	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—HRAS—skin cancer	1.38e-05	0.00259	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—skin cancer	1.37e-05	0.00257	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—IL6—skin cancer	1.36e-05	0.00255	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SUFU—skin cancer	1.36e-05	0.00255	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—HRAS—skin cancer	1.33e-05	0.0025	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—HRAS—skin cancer	1.33e-05	0.0025	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—IL6—skin cancer	1.32e-05	0.00248	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—KRAS—skin cancer	1.31e-05	0.00246	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—IL6—skin cancer	1.31e-05	0.00246	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—KRAS—skin cancer	1.3e-05	0.00245	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—NRAS—skin cancer	1.3e-05	0.00243	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—IL6—skin cancer	1.28e-05	0.0024	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—IL6—skin cancer	1.28e-05	0.0024	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—FOXO4—skin cancer	1.26e-05	0.00237	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—skin cancer	1.26e-05	0.00235	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—NRAS—skin cancer	1.24e-05	0.00233	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CSPG4—skin cancer	1.23e-05	0.0023	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—NRAS—skin cancer	1.22e-05	0.00229	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—FOXO4—skin cancer	1.21e-05	0.00227	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—FOXO4—skin cancer	1.21e-05	0.00226	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—HRAS—skin cancer	1.2e-05	0.00225	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—skin cancer	1.2e-05	0.00225	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	1.18e-05	0.00222	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—BRAF—skin cancer	1.17e-05	0.0022	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—NRAS—skin cancer	1.17e-05	0.00219	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—NRAS—skin cancer	1.16e-05	0.00218	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—NRAS—skin cancer	1.15e-05	0.00216	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—IL6—skin cancer	1.15e-05	0.00215	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—NRAS—skin cancer	1.15e-05	0.00215	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTCH2—skin cancer	1.13e-05	0.00212	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	1.13e-05	0.00212	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—skin cancer	1.13e-05	0.00212	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—HRAS—skin cancer	1.12e-05	0.00209	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—KRAS—skin cancer	1.12e-05	0.00209	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.11e-05	0.00208	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—HRAS—skin cancer	1.11e-05	0.00208	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	1.08e-05	0.00203	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—NRAS—skin cancer	1.08e-05	0.00203	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—NRAS—skin cancer	1.08e-05	0.00203	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—CDKN2A—skin cancer	1.08e-05	0.00202	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—NRAS—skin cancer	1.07e-05	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—IL6—skin cancer	1.07e-05	0.002	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KRAS—skin cancer	1.07e-05	0.002	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—skin cancer	1.06e-05	0.00199	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—IL6—skin cancer	1.06e-05	0.00199	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—NRAS—skin cancer	1.06e-05	0.00198	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—skin cancer	1.06e-05	0.00198	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—KRAS—skin cancer	1.05e-05	0.00197	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SHH—skin cancer	1.04e-05	0.00195	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RASA1—skin cancer	1.03e-05	0.00193	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PLIN2—skin cancer	1.01e-05	0.00189	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—KRAS—skin cancer	1e-05	0.00188	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—NRAS—skin cancer	1e-05	0.00188	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	9.99e-06	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—KRAS—skin cancer	9.99e-06	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—KRAS—skin cancer	9.94e-06	0.00186	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—KRAS—skin cancer	9.89e-06	0.00185	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SMO—skin cancer	9.84e-06	0.00184	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTCH1—skin cancer	9.84e-06	0.00184	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	9.75e-06	0.00183	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTGER4—skin cancer	9.58e-06	0.0018	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	9.57e-06	0.0018	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—HRAS—skin cancer	9.49e-06	0.00178	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—skin cancer	9.39e-06	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—HRAS—skin cancer	9.33e-06	0.00175	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KRAS—skin cancer	9.3e-06	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KRAS—skin cancer	9.3e-06	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	9.3e-06	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—KRAS—skin cancer	9.22e-06	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—skin cancer	9.14e-06	0.00171	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—KRAS—skin cancer	9.1e-06	0.00171	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—IL6—skin cancer	9.08e-06	0.0017	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—skin cancer	9.08e-06	0.0017	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—HRAS—skin cancer	8.93e-06	0.00167	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—IL6—skin cancer	8.69e-06	0.00163	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—KRAS—skin cancer	8.61e-06	0.00161	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERCC2—skin cancer	8.61e-06	0.00161	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GLI2—skin cancer	8.59e-06	0.00161	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—HRAS—skin cancer	8.57e-06	0.00161	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—IL6—skin cancer	8.55e-06	0.0016	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—HRAS—skin cancer	8.53e-06	0.0016	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—HRAS—skin cancer	8.49e-06	0.00159	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	8.49e-06	0.00159	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FOXO4—skin cancer	8.46e-06	0.00159	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—HRAS—skin cancer	8.45e-06	0.00158	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—HRAS—skin cancer	8.41e-06	0.00158	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SHH—skin cancer	8.33e-06	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ENO2—skin cancer	8.33e-06	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	8.28e-06	0.00155	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	8.24e-06	0.00154	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MC1R—skin cancer	8.19e-06	0.00154	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—IL6—skin cancer	8.16e-06	0.00153	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—IL6—skin cancer	8.12e-06	0.00152	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CSPG4—skin cancer	8.1e-06	0.00152	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—IL6—skin cancer	8.08e-06	0.00152	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GLI1—skin cancer	8.07e-06	0.00151	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TERT—skin cancer	8.07e-06	0.00151	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—IL6—skin cancer	8.05e-06	0.00151	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—HRAS—skin cancer	7.91e-06	0.00148	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—HRAS—skin cancer	7.91e-06	0.00148	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	7.91e-06	0.00148	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	7.87e-06	0.00148	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—HRAS—skin cancer	7.84e-06	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—skin cancer	7.77e-06	0.00146	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—HRAS—skin cancer	7.73e-06	0.00145	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SUFU—skin cancer	7.65e-06	0.00143	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—IL6—skin cancer	7.57e-06	0.00142	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	7.57e-06	0.00142	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—IL6—skin cancer	7.57e-06	0.00142	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—IL6—skin cancer	7.5e-06	0.00141	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—IL6—skin cancer	7.43e-06	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—IL6—skin cancer	7.4e-06	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—NRAS—skin cancer	7.36e-06	0.00138	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FOXO4—skin cancer	7.36e-06	0.00138	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—HRAS—skin cancer	7.32e-06	0.00137	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PLIN2—skin cancer	7.27e-06	0.00136	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	7e-06	0.00131	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FOXO4—skin cancer	6.79e-06	0.00127	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	6.7e-06	0.00126	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—BRAF—skin cancer	6.39e-06	0.0012	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KRAS—skin cancer	6.34e-06	0.00119	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—skin cancer	6.01e-06	0.00113	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CSPG4—skin cancer	5.86e-06	0.0011	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SHH—skin cancer	5.84e-06	0.00109	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RASA1—skin cancer	5.8e-06	0.00109	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TERT—skin cancer	5.65e-06	0.00106	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	5.63e-06	0.00106	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SMO—skin cancer	5.53e-06	0.00104	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTCH1—skin cancer	5.53e-06	0.00104	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ENO2—skin cancer	5.51e-06	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—IL6—skin cancer	5.5e-06	0.00103	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PLIN2—skin cancer	5.48e-06	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—skin cancer	5.39e-06	0.00101	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTGER4—skin cancer	5.39e-06	0.00101	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PLIN2—skin cancer	5.17e-06	0.000969	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—skin cancer	5.16e-06	0.000968	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—IL6—skin cancer	5.16e-06	0.000967	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERCC2—skin cancer	4.84e-06	0.000908	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FOXO4—skin cancer	4.76e-06	0.000892	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TERT—skin cancer	4.54e-06	0.000851	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—BRAF—skin cancer	4.47e-06	0.000839	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CSPG4—skin cancer	4.42e-06	0.000829	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NRAS—skin cancer	4.2e-06	0.000787	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CSPG4—skin cancer	4.17e-06	0.000781	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NRAS—skin cancer	4.03e-06	0.000756	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NRAS—skin cancer	4.02e-06	0.000753	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ENO2—skin cancer	3.98e-06	0.000747	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.77e-06	0.000707	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—skin cancer	3.61e-06	0.000678	CbGpPWpGaD
Temsirolimus—MTOR—Disease—BRAF—skin cancer	3.59e-06	0.000674	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—skin cancer	3.47e-06	0.000651	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—skin cancer	3.46e-06	0.000648	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PLIN2—skin cancer	3.38e-06	0.000634	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.35e-06	0.000628	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ERCC2—skin cancer	3.2e-06	0.0006	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TERT—skin cancer	3.18e-06	0.000596	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—skin cancer	3.07e-06	0.000576	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO2—skin cancer	3e-06	0.000563	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—skin cancer	2.95e-06	0.000553	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—IL6—skin cancer	2.94e-06	0.000551	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—skin cancer	2.94e-06	0.000551	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—skin cancer	2.9e-06	0.000544	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO2—skin cancer	2.83e-06	0.000531	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—skin cancer	2.81e-06	0.000527	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—IL6—skin cancer	2.81e-06	0.000527	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CSPG4—skin cancer	2.72e-06	0.000511	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—BRAF—skin cancer	2.52e-06	0.000472	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—skin cancer	2.45e-06	0.000459	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—skin cancer	2.42e-06	0.000454	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ERCC2—skin cancer	2.31e-06	0.000434	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—skin cancer	2.26e-06	0.000423	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—skin cancer	2.15e-06	0.000403	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—skin cancer	2.11e-06	0.000395	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—skin cancer	2.06e-06	0.000386	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL6—skin cancer	1.97e-06	0.000369	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—skin cancer	1.94e-06	0.000364	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—skin cancer	1.92e-06	0.00036	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO2—skin cancer	1.85e-06	0.000347	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—skin cancer	1.79e-06	0.000336	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ERCC2—skin cancer	1.75e-06	0.000327	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL6—skin cancer	1.71e-06	0.000321	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—skin cancer	1.65e-06	0.00031	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ERCC2—skin cancer	1.64e-06	0.000308	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—skin cancer	1.58e-06	0.000297	CbGpPWpGaD
Temsirolimus—MTOR—Disease—IL6—skin cancer	1.58e-06	0.000297	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—skin cancer	1.39e-06	0.00026	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—skin cancer	1.36e-06	0.000255	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—skin cancer	1.21e-06	0.000227	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—skin cancer	1.16e-06	0.000217	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL6—skin cancer	1.11e-06	0.000208	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ERCC2—skin cancer	1.08e-06	0.000202	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—skin cancer	1.05e-06	0.000196	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—skin cancer	9.86e-07	0.000185	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—skin cancer	6.45e-07	0.000121	CbGpPWpGaD
